SPECIFICS OF TREATING LIVER DISEASES AND THE RELEVANCE OF IMPROVING THERAPEUTIC MEASURES

Authors

  • Sokhib Zamon o'g'li Rashidov Department of the pharmacology of the Tashkent state medical university
  • Javokhir Rustamovich Mamashov Tashkent state medical university
  • Umidjon Khabib oʻgʻli Abduqakhkhorov Tashkent state medical university

DOI:

https://doi.org/10.5281/zenodo.20390053

Keywords:

Autophagy, gene therapy, anti-hepatic stellate cells, liver diseases, Cell treatment, effective therapeutic interventions.

Abstract

One of the most prevalent pathological issues in the globe is liver disease. Over 1.5 billion people worldwide are impacted by it. Hepatocytes, Kupffer cells, sinusoidal endothelial cells, and hepatic stellate cells (HSCs) are among the several hepatic cell types that have been linked to the development and spread of both acute and chronic liver disorders. Autophagy, fibrogenic factors, cytokines, oxidative stress, and microRNAs are also implicated. Finding novel therapeutic approaches that may be applied in clinical settings is made possible by comprehending the basic pathways behind liver illnesses. Liver illnesses, both acute and chronic, are global issues with complex etiologies. There is still uncertainty regarding the precise pathogenic mechanism behind a number of liver illnesses. Nevertheless, a number of hypothesized mechanisms—such as oxidative stress, inflammation, autophagy, and microRNA—are implicated. The development of novel and successful therapeutic solutions for this bothersome issue is aided by the underlying viewpoint mechanisms. Antioxidant, anti-inflammatory, anti-HSC therapy, gene therapy, cell therapy, gut microbiota, and nanoparticles have recently shown significant promise in the prevention and treatment of liver disorders. The pathophysiology of acute and chronic liver illnesses was examined here, along with recent potential molecular pathways. Additionally, we highlighted recent research on the treatment of liver problems and reviewed recent therapeutic strategies that targeted liver diseases. This review also provides updates on novel diagnostic methods, existing therapies, and possible therapeutic targets that are currently being tested in clinical settings. The development of new therapeutic approaches will benefit greatly from recent developments in our understanding of the pathophysiology of liver diseases.

Downloads

Download data is not yet available.

References

1.Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.

2.Ali FE, Abd El-Aziz MK, Sharab EI, Bakr AG. Therapeutic interventions of acute and chronic liver disorders: A comprehensive review. World J Hepatol. 2023 Jan 27;15(1):19-40. doi: 10.4254/wjh.v15.i1.19.

3.Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761

4.Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670

5.Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01

6.Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07

7.Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06

8.Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863

9.Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820

10.Sokhib Rashidov Zamon oʻgʻli, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o‘g‘li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856

11.Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434

12.Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577

13.Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.

14.Sokhib Rashidov Zamon oʻgʻli, Nilufar Ergasheva Agʼzamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065

15.Sokhib Rashidov Zamon oʻgʻli, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Poʻlatjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141

16.Sokhib Rashidov Zamon oʻgʻli, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142

17.Sokhib Rashidov Zamon oʻgʻli, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.

18.Sokhib Rashidov Zamon oʻgʻli, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qoʻshbekova Roʻzimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857

19.Sah AK, Afzal M, Elshaikh RH, Abbas AM, Shalabi MG, Prabhakar PK, Babker AMA, Khalimova FT, Sabrievna VA, Choudhary RK. Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes. Life. 2025; 15(5):779. https://doi.org/10.3390/life15050779

20.Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clin Liver Dis (Hoboken) 2021;17:365–370. doi: 10.1002/cld.1061.

21.Gan, C., Yuan, Y., Shen, H. et al. Liver diseases: epidemiology, causes, trends and predictions. Sig Transduct Target Ther 10, 33 (2025). https://doi.org/10.1038/s41392-024-02072-z

22.Ashenhurst, J. R. et al. Prevalence of alpha-1 antitrypsin deficiency, self-reported behavior change, and health care engagement among direct-to-consumer recipients of a personalized genetic risk report. Chest 161, 373–381 (2022).

23.Hasegawa, K. et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol. Res. 53, 383–390 (2023).

24.Giannitrapani, L. et al. The changing epidemiology of hepatocellular carcinoma : experience of a single center. Biomed. Res. Int. 2020, 5309307 (2020).

25.Santos, A. A. et al. Spatial metabolomics and its application in the liver. Hepatology 79, 1158–1179 (2024).

26.Han, H. et al. Danger signals in liver injury and restoration of homeostasis. J. Hepatol. 73, 933–951 (2020).

27.Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516–537 (2023).

28.Tapper, E. B. & Parikh, N. D. Diagnosis and management of cirrhosis and its complications: a review. JAMA 329, 1589–1602 (2023).

Downloads

Published

2026-05-26

How to Cite

SPECIFICS OF TREATING LIVER DISEASES AND THE RELEVANCE OF IMPROVING THERAPEUTIC MEASURES. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(5), 1800-1802. https://doi.org/10.5281/zenodo.20390053

Similar Articles

41-50 of 1807

You may also start an advanced similarity search for this article.